Ranbaxy Laboratories Ltd. has received regulatory drug approval for its anti-malarial drug, Synriam, in 7 countries including Nigeria. According to Ranbaxy, the drug provides relief from most malaria-related symptoms, including fever, and has a high cure rate of over 95 per cent. Other countries on the African continent that have granted approval for the new drug are Cameroon, Guinea, Ivory Coast, Kenya, Senegal and Uganda.
About Bob Aroture 564 Articles
Bob is a Senior Editor and Content Development Manager at Nigerian Law Intellectual Property Watch. He holds a BS degree, with a major in biochemistry. He works directly with the Newsroom Team. His focus areas are technology and innovation, and pharmaceutical technology. Email: email@example.com